Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesOnce-Weekly Administration of Etanercept 50 mg Improves Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis
Dermatology, 10/23/09
Reich K et al. – Patients with moderate–to–severe psoriasis entered this trial with serious PRO impairment. At week 12, etanercept 50 mg QW provided significant QoL improvements compared with placebo. After 24 weeks of etanercept, the patients' serious PRO impairment had largely abated.
Related Articles
Pediatric psoriasis: an update
Therapeutics and Clinical Risk Management, 10/22/09
Relevance Score: 95%
FDA Approves New Drug to Treat Psoriasis
Internet Source, 11/02/09
Relevance Score: 91%
Study shows major burden of psoriasis
Internet Source, 10/29/09
Relevance Score: 91%
Prevalence of myocardial infarction in patients with psoriasis in central China
Journal of the European Academy of Dermatology and Venereology, 10/27/09
Relevance Score: 91%
Why nail psoriasis remains difficult to treat
Dermatology in Practice, 10/12/09
Relevance Score: 91%
Today in Dermatology...keeping you current
Receive free subspecialty "5-minute updates" via email
The Influence of Environmental Temperature on the Response of the Skin to Local Pressure: The Impact of Aging and Diabetes
Diabetes Technology & Therapeutics, 12/16/09
Lymphatic and blood vessels in scleroderma skin, a morphometric analysis
Human Pathology, 12/16/09
Outcomes of Childhood Hemangiomas Treated with the Pulsed-Dye Laser with Dynamic Cooling: A Retrospective Chart Analysis
Dermatologic Surgery, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor